FDA Aims Neglected Tropical Disease Guidance At Inexperienced Sponsors
This article was originally published in PharmAsia News
Executive Summary
Big pharma is not the prime player in the tropical disease area, even as some large firms increase funding.
You may also be interested in...
FDA Adds Three “Qualifying Pathogens” For Potential Antibiotic Incentives
Final rule includes a total of 21 pathogens, but agency notes a drug intended to treat a pathogen on the list is not guaranteed a QIDP designation for priority review and potential added marketing exclusivity.
FDA Cuts Priority Review Voucher Fee By 32%; No Takers For FY 2013
By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.